L-DEP regimen as a salvage therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15007481

Enrollment

Unknown

Registered

2015-11-29

Start date

2015-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemophagocytic Lymphohistiocytosis

Interventions

L-DEP:L-DEP regimen

Eligibility

Sex/Gender

All

Age

14 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients were older than 14 years of age; 2. diagnosed as EBV-HLH; 3. Patients did not achieve at lease partial response after initial treatment including HLH-94 or DEP no less than 2 weeks; 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Heart function above grade II (NYHA); 2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2; 3. Pregnancy or lactating Women; 4. Allergic to Pegaspargase, doxorubicin or etopside; 5. Active bleeding of the internal organs; 6. uncontrollable infection; 7. history of acute and chronic pancreatitis; 8. Participate in other clinical research at the same time.

Design outcomes

Primary

Measure	Time frame
white blood cell;neutrophil;hemoglobin;thrombocyte;ferritin;triglyceride;fibrinogen;glutamic-pyruvic transaminase;total bilirubin;hemophagocytosis;NK activity;sCD25;EBV-DNA;	—

Countries

China

Contacts

Public ContactWang Zhao

zhaowww263@yahoo.com+86 13910623679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026